Thyroid disorders are closely linked to gastrointestinal (GI) dysmotility. Both hypo- and hyperthyroidism can affect GI motility, altering the structure and function of the pharynx, esophagus, and regulating esophageal peristalsis through neuro-humoral interactions. Hyperthyroidism is associated with delayed gastric emptying and malabsorption, while hypothyroidism is linked to constipation. Thyroid hormones, particularly thyroxine (T4) and triiodothyronine (T3), influence GI motility by acting on muscle cell receptors. Hypothyroidism can lead to delayed gastric emptying, reduced acid secretion, and bacterial overgrowth in the small intestine, while hyperthyroidism may cause increased stool frequency and diarrhea. GI dysmotility symptoms can be subtle and may be the only sign of thyroid disease. Thyroid hormone replacement therapy can improve GI motility symptoms in hypothyroid patients. However, factors such as altered T4 absorption due to gastric physiology can affect treatment effectiveness. Improving GI health, such as through probiotics or dietary changes, can enhance thyroid medication absorption and reduce the need for higher doses. The relationship between thyroid disorders and GI dysmotility is complex, involving both direct and indirect mechanisms, including autonomic nervous system responses. Understanding this relationship is crucial for the diagnosis and treatment of thyroid-related GI symptoms.Thyroid disorders are closely linked to gastrointestinal (GI) dysmotility. Both hypo- and hyperthyroidism can affect GI motility, altering the structure and function of the pharynx, esophagus, and regulating esophageal peristalsis through neuro-humoral interactions. Hyperthyroidism is associated with delayed gastric emptying and malabsorption, while hypothyroidism is linked to constipation. Thyroid hormones, particularly thyroxine (T4) and triiodothyronine (T3), influence GI motility by acting on muscle cell receptors. Hypothyroidism can lead to delayed gastric emptying, reduced acid secretion, and bacterial overgrowth in the small intestine, while hyperthyroidism may cause increased stool frequency and diarrhea. GI dysmotility symptoms can be subtle and may be the only sign of thyroid disease. Thyroid hormone replacement therapy can improve GI motility symptoms in hypothyroid patients. However, factors such as altered T4 absorption due to gastric physiology can affect treatment effectiveness. Improving GI health, such as through probiotics or dietary changes, can enhance thyroid medication absorption and reduce the need for higher doses. The relationship between thyroid disorders and GI dysmotility is complex, involving both direct and indirect mechanisms, including autonomic nervous system responses. Understanding this relationship is crucial for the diagnosis and treatment of thyroid-related GI symptoms.